Published online Mar 6, 2019. doi: 10.12998/wjcc.v7.i5.585
Peer-review started: December 20, 2018
First decision: January 12, 2019
Revised: February 2, 2019
Accepted: February 18, 2019
Article in press: February 18, 2019
Published online: March 6, 2019
Processing time: 79 Days and 1.6 Hours
Resistin is most likely involved in the pathogenesis of gestational diabetes mellitus (GDM), but the existing findings are inconsistent.
To explore the sources of heterogeneity in the existing literature, we made the literature heterogeneity within an acceptable range by setting reasonable inclusion criteria. Based on this, we aimed to explore the relationship between serum level of resistin and GDM risk.
This article aims to review the studies investigating the association of GDM risk with serum resistin level.
A systematic literature search was performed using MEDLINE, EMBASE, and Web of Science (all databases). We did subgroup analysis according to the need for insulin in GDM patients and gestational age at blood sampling. Meta-regression with restricted maximum likelihood estimation was performed to assess the potentially important covariate exerting substantial impact on between-study heterogeneity.
The meta-analysis included 18 studies (22 comparisons) with 1041 cases and 1292 controls. The total results showed that the risk of GDM was associated with serum resistin level. The results of subgroup are consistent with the total results. The meta-regression revealed that no need for insulin in GDM patients, age distribution similar between cases and controls, and ELISA all had a significant impact on between-study heterogeneity.
This meta-analysis supports that the maternal serum resistin level is associated with GDM risk.
In summary, our meta-analysis showed that higher maternal serum resistin level is related to GDM risk and suggested that the serum level of resistin may be related to the severity of GDM.